Physician profile
Michael A Patterson
NPI 1699857151
$7,413.84
in general payments reported to CMS, 2019-2025
36 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $634 · 2021: $1,313 · 2022: $1,435 · 2023: $1,669 · 2024: $1,337 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,856.82 | 2021-2025 | |
| Pfizer INC. | $785.42 | 2019-2024 | |
| Novo Nordisk INC | $558.85 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $544.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $442.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $347.13 | 2019-2024 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $325.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $293.94 | 2020-2021 | |
| Amgen INC. | $174.45 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $122.61 | 2020-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $90.39 | 2019-2023 | Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $83.47 | 2021-2023 | |
| Abbott Laboratories | $67.56 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.17 | 2019-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $58.05 | 2023-2025 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $46.69 | 2020 | |
| Astellas Pharma US INC | $45.44 | 2019 | |
| Eisai INC. | $44.16 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.12 | 2019-2021 | |
| Exact Sciences Corporation | $34.96 | 2023-2024 | Cologuard Collection Kit |
| Bausch & Lomb Americas INC. | $34.82 | 2022 | |
| Nevro Corp. | $34.47 | 2023 | Senza |
| Janssen Pharmaceuticals, INC | $34.44 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $32.69 | 2022-2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $30.75 | 2023 | |
| Arbor Pharmaceuticals, INC. | $25.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.53 | 2022 | |
| Aimmune Therapeutics, INC. | $21.94 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $17.84 | 2023 | Injectafer |
| Endo Pharmaceuticals INC. | $17.74 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.88 | 2025 | Azmiro |
| Aytu Biopharma, INC. | $14.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.03 | 2019 | |
| Almatica Pharma LLC | $13.93 | 2024 | Loreev Xr |
| Horizon Therapeutics Plc | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.